<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722384</url>
  </required_header>
  <id_info>
    <org_study_id>ACU101</org_study_id>
    <nct_id>NCT00722384</nct_id>
  </id_info>
  <brief_title>Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5</brief_title>
  <official_title>An Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5 by Single Intravitreal Injection in Patients With Wet Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the tolerability and preliminary efficacy of Cand5 by a single intravitreal
      injection in patients with wet age-related macular degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complications, including those related to the intravitreal injection, and adverse events, and loss of lines of best-corrected visual acuity, slit lamp findings, lens opacification, intraocular pressure, fundus findings, and laboratory findings.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stabilization of visual acuity (prevention of loss of three or more lines on the ETDRS chart), stabilization of lesion size, lack of leakage of lesion, or decrease in subretinal fluid</measure>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mg bevasiranib in the study eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.33 mg bevasiranib in the study eye,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg bevasiranib in the study eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg bevasiranib in the study eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg bevasiranib in the study eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevasiranib</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <other_name>Cand5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevasiranib</intervention_name>
    <description>The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with subfoveal predominantly classic, minimally classic and purely occult
             lesions, secondary to age related macular degeneration, with a total lesion size
             (including blood, atrophy/scar and neovascularization) of &lt; 12 total disc areas, of
             which at least 50% are active CNV.

          -  Patients must have visual acuity 20/50 to 20/320 in the study eye.

          -  Patients must have better visual acuity in the fellow eye than the study eye.

          -  Subretinal hemorrhage (if any) must comprise no more than 50% of total lesion size.

        Exclusion Criteria:

          -  Patients with concomitant eye disease, including glaucoma, uveitis, diabetic
             retinopathy, presence of pigment epithelial tears or rips, acute ocular or periocular
             infection in the study eye.

          -  Patients with &gt; 3 prior PDT treatments with Visudyne in the study eye.

          -  Patients who received PDT in the study eye within eight weeks prior to the baseline
             angiography/photography.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>OPKO site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2008</study_first_posted>
  <last_update_submitted>July 24, 2008</last_update_submitted>
  <last_update_submitted_qc>July 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Denis O'Shaughnessy</name_title>
    <organization>Opko Health</organization>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Opko Health</keyword>
  <keyword>Acuity Pharmaceuticals</keyword>
  <keyword>bevasiranib</keyword>
  <keyword>Cand5</keyword>
  <keyword>Age-Related</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

